



## **ARM and JSRM Announce Agreement to Foster Scientific Collaboration for Regenerative Medicine Between the U.S. and Japan**

**Boston, MA – June 16, 2025**

The Alliance for Regenerative Medicine (ARM) and the Japanese Society for Regenerative Medicine (JSRM) announce a Memorandum of Understanding to facilitate research, partnerships, and advocacy between enterprises and academic institutions in regenerative medicine and cell and gene therapy.

Global collaboration is critical to the continued global advancement of cell and gene therapies. With Japan serving as a long-standing leader in regenerative medicine innovation, ARM's partnership with JSRM reflects a shared commitment to accelerating scientific progress, promoting knowledge exchange, and expanding patient access to advanced therapies worldwide.


These priorities closely align with ARM's priorities supporting the growth of cell and gene therapies within global healthcare systems and the sector's expansion into the Asia-Pacific region. By working with JSRM, ARM will help foster a more connected and informed global regenerative medicine community, enabling coordinated progress in scientific research, clinical development, and regulatory frameworks.

*"As the cell and gene therapy ecosystem becomes increasingly global, Japan continues to be a critical hub for innovation and leadership in our field,"* said ARM Chief Executive Officer Tim Hunt. *"JSRM is at the forefront of advancing science, policy, and public understanding in Japan, and this partnership reflects our shared commitment to expanding international cooperation and improving access to transformative therapies for patients worldwide."*

*"This partnership with ARM marks a meaningful step forward in our commitment to global collaboration in regenerative medicine,"* said Kyosuké Mano, Secretary General of JSRM. *"ARM and JSRM each hold strong influence over how advanced therapies are shaped within robust regulatory environments—ARM through its global industry alliances, and JSRM through its academic and ethical integration. Together, we are well-positioned to promote responsible innovation and accelerate harmonized approaches that benefit patients across systems and borders. This partnership strengthens our collective capacity to build coherent, globally informed pathways across Japan, Greater Asia, and the international community."*

### **About the Alliance for Regenerative Medicine**

The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society. As a community, ARM builds the future of medicine by convening the sector, facilitating influential exchanges on policies and practices, and advancing the narrative with data and analysis. We actively engage key stakeholders to enable the development of



advanced therapies and modernize healthcare systems so that patients benefit from durable, potentially curative treatments.

As the sector's global voice, we represent more than 400 members in 25 countries, including emerging and established biotechnology companies, academic and medical research institutions, and patient organizations.

**About the Japanese Society for Regenerative Medicine (JSRM)**

The Japanese Society for Regenerative Medicine (JSRM) is the largest academic society in regenerative medicine globally, with over 6,000 members spanning diverse fields, including basic and clinical sciences, tissue engineering, bioethics, regulatory science, and health policy. JSRM serves as a multidisciplinary platform for researchers, clinicians, industry leaders, and policymakers to collaborate on regenerative medicine development and implementation. The society actively engages in policy advocacy, develops industry standards, and hosts international academic conferences to drive scientific and regulatory advancements in regenerative medicine.